Heart Failure Risk Reduction in Diabetes: What the Practicing Endocrinologist Should Know

Expert faculty discuss the latest data on using SGLT2 inhibitors to reduce HF risk in patients with T2D
Jennifer B. Green, MD
Mikhail N. Kosiborod, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 3.16 MB
Released: June 7, 2021

Acknowledgements

Provided by the Endocrine Society

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

This activity is supported by an independent educational grant from
Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company

Related Content

Diabetes technology health tools for patients and caregivers, provided by the Endocrine Society.

Released: November 9, 2021

From Dr. Carol Hatch Wysham and Clinical Care Options (CCO), expert commentary on improving care for type 2 diabetes

Carol Hatch Wysham, MD Released: October 7, 2021

Short video from Clinical Care Options (CCO) featuring expert insights on the clinical management of persons with T2D and metabolic comorbidities

Carol Hatch Wysham, MD Physicians: maximum of 0.5 AMA PRA Category 1 Credits Registered Nurses: 0.5 Nursing contact hours Pharmacists: 0.5 contact hours (0.05 CEUs) Registered Dietitians/Dietetic Technicians, Registered: maximum of 0.5 CPEU(s) Released: September 30, 2021 Expired: September 29, 2022

From Dr. Carol Hatch Wysham and Clinical Care Options (CCO), expert commentary on emerging data on tirzepatide for type 2 diabetes

Carol Hatch Wysham, MD Released: September 21, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings